The present invention includes compositions and method of treating a textile with an antimicrobial agent, the method comprising contacting the textile with an antimicrobial agent that comprises a reactive dye or crosslinking agent comprising an organo-selenium compound in a treatment solution.
D06P 1/384 - Procédés généraux de teinture ou d'impression des textiles ou procédés généraux de teinture du cuir, des fourrures ou des substances macromoléculaires solides de toutes formes, classés selon les teintures, les pigments ou les substances auxiliaires utilisés utilisant des colorants réactifs le groupe réactif n'étant pas directement lié au groupe hétérocyclique
A01N 25/34 - Formes façonnées, p. ex. feuilles, non prévues dans l'un quelconque des autres sous-groupes du présent groupe principal
A01N 55/00 - Biocides, produits repoussant ou attirant les animaux nuisibles ou régulateurs de croissance des végétaux, contenant des composés organiques comportant des éléments autres que le carbone, l'hydrogène, les halogènes, l'oxygène, l'azote et le soufre
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
D06P 3/00 - Procédés particuliers de teinture ou d'impression de textiles ou de teinture du cuir, des fourrures ou de substances macromoléculaires solides de toutes formes classés selon la matière traitée
A fast startup baseband amplifier includes an input buffer and DC offset circuit having either one or two diodes or two MOSFETs, an input and an output, and a baseband amplifier having an input coupled to the output of the input buffer and DC offset circuit. The fast startup baseband amplifier can be used in a microwave passive sensor or system, and a method for passively detecting a movement of a target.
H03F 3/10 - Amplificateurs comportant comme éléments d'amplification uniquement des tubes à décharge ou uniquement des dispositifs à semi-conducteurs comportant uniquement des dispositifs à semi-conducteurs avec des diodes
H03F 3/195 - Amplificateurs à haute fréquence, p. ex. amplificateurs radiofréquence comportant uniquement des dispositifs à semi-conducteurs dans des circuits intégrés
3.
SYSTEM AND METHOD FOR INCREASING A STORAGE CAPACITY OF AN UNDERGROUND STORAGE RESERVOIR USING AN ELECTRICAL SUBMERSIBLE PUMP
A system and method for increasing a storage capacity of a first underground storage reservoir includes a first well having perforations within the first underground storage reservoir, a second well having first perforations within the first underground storage reservoir and second perforations within a second underground storage reservoir, and an electrical submersible pump. The first well is configured to inject a gas, liquefied gas or supercritical fluid into the first underground storage reservoir. The electrical submersible pump is located within the second well and increases the storage capacity of the first underground storage reservoir by transferring a fluid from the first underground storage reservoir to the second underground storage reservoir.
Embodiments described herein provide for high frequency transmission spectroscopy (HFTS) system and methods. The HFTS system and methods provided herein allow for identification or classification of materials of interest in a wide range of industries. The HFTS system and methods are capable of identifying unknown particles, characterizing particle size/charge, or monitoring solutions for specific materials in semiconductor, biomedical, and environmental applications. The HFTS system includes an ENA operable to generate an AC as an excitation signal and sweep a frequency of the AC from an initial frequency to a final frequency. A test cell operable to retain a MOI is positioned between an input antenna and an output antenna. The ENA is configured to calculate parameters at each frequency step to plot magnitude response and/or phase response for identification or classification.
A method and system for the recovery of rare earth elements, cobalt, and electrolytic iron from magnets. The system can include an electrochemical cell assembly configured to dissolve the magnets in an acid solution. The system can also include a filtration unit operatively connected to the electrochemical cell assembly for removing impurities from the dissolved magnet solution. The system can also include a precipitation unit operatively connected to the filtration unit. The system can also include an electrowinning cell operatively connected to the precipitation unit. The system can also include a recycling unit for regenerating sulfuric acid from the process effluent, operatively connected to the electrowinning cell.
C22B 3/04 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation
C22B 3/22 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques
C22B 3/44 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés chimiques
B09B 3/00 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif
C22B 59/00 - Obtention des métaux des terres rares
C25C 1/06 - Production, récupération ou affinage électrolytique des métaux par électrolyse de solutions des métaux du groupe du fer, de métaux réfractaires ou du manganèse
C25C 1/08 - Production, récupération ou affinage électrolytique des métaux par électrolyse de solutions des métaux du groupe du fer, de métaux réfractaires ou du manganèse du nickel ou du cobalt
C25C 1/22 - Production, récupération ou affinage électrolytique des métaux par électrolyse de solutions des métaux non prévus dans les groupes
C25C 7/00 - Éléments structurels, ou leur assemblage, des cellulesEntretien ou conduite des cellules
Embodiments pertain to a composition suitable for use in treating or preventing a metabolic disorder in a subject. The composition may include a therapeutically effective amount of indacaterol, pharmaceutically acceptable salts thereof, pharmaceutically acceptable hydrates thereof, or combinations thereof. The composition may also include at least one glucagon-like peptide- 1 (GLP-1) agonist. Additional embodiments pertain to methods of treating or preventing a metabolic disorder in a subject by administering to the subject a composition of the present disclosure.
Embodiments are directed to ammonia absorbers and associated methods of producing the same, the ammonia absorbers comprising a homogeneous mixture of aluminum fibers and anhydrous powdered magnesium chloride pressed into pellets.
B01J 20/02 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
A neutron detector for detecting neutrons with energies from meV to tens of MeV comprising one or more nitride (BN) strips electrically connected in parallel or series. In some embodiments, the two or more BN strips are stacked on one another. In other embodiments, the two or more BN strips are disposed on a substrate with a gap between the two or more BN strips.
33 - Boissons alcoolisées à l'exception des bières
35 - Publicité; Affaires commerciales
27 - Revêtements de sols et de murs
14 - Métaux précieux et leurs alliages; bijouterie; horlogerie
16 - Papier, carton et produits en ces matières
18 - Cuir et imitations du cuir
20 - Meubles et produits décoratifs
21 - Ustensiles, récipients, matériaux pour le ménage; verre; porcelaine; faience
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Bed blankets; Plastic banners; Vinyl banners; Plastic pennants; Felt pennants; Bed sheets; Throws; Kitchen towels; Dining linens; Fabric flags; Dust ruffles; Draperies; Cotton fabrics; Duvets; Pillow covers; Bath towels; Towels; Pillow shams; Baby bedding, namely, bundle bags, swaddling blankets, crib bumpers, fitted crib sheets, crib skirts, crib blankets, and diaper changing pad covers not of paper; Nylon flags; Beach towels T-shirts; Fleece tops; Fleece jackets; Fleece pullovers; Fleece bottoms; Fleece vests; Shorts; Pants; Track jackets; Outer jackets; Sports jackets; Rain jackets; Clothing jackets; Clothing jacket liners; Denim jackets; Coats; Socks; Gloves for apparel; Caps being headwear; Visors being headwear; Headwear for babies, adults, children, men and women; Shoes; Scarves; Sleepwear; Loungewear; Belts for clothing Swimming pool air floats; Ordinary playing cards; Dog toys; Bobblehead dolls; Play balls and play balloons; Billiard tables; Golf club bags; Basketball hoops; Toy vehicles; Plush toys with attached comfort blanket; Card games; Golf club head covers; Softball bats; Stuffed toy animals; Christmas dolls; Miniature toy sports games; Golf putters; Soccer balls; Foosball tables; Ring games; Dart games; Memory games; Dice games; Basketballs; Water globes; Baseball bats; Sport balls; Stuffed toys; Plush toys; Toy figures; Cornhole game boards; Cornhole bags; Puzzle board games; Table tennis balls; Golf tees; Golf clubs; Golf balls; Golf ball markers; Golf bags; Pool cushions; Nutcracker dolls Beer; Sports drinks; Drinking water Wine; Ready-to-drink alcoholic beverages, other than beer-based; Whiskey; Rum; Vodka; Distilled blue agave liquor; Bourbon Sports recruiting services for Texas Tech Athletics prospective student athletes; Promotion of goods and services through sponsorship of sports events; Promoting the goods and services of others by arranging for sponsors to affiliate their goods and services with Texas Tech Athletics; Selecting athletes for placement on Texas Tech Athletic teams; Promotional advertising of products and services of third parties through sponsoring arrangements and license agreements relating to Texas Tech Athletics; Recruitment of students for higher education institutions; Providing business information via a website; Promoting the goods and services of others by providing hypertext links to the web sites of others; Sales promotion Carpeting; Bath mats; Door mats; Artificial turf; Wallpaper; Area rugs Costume jewelry; Memorial jewelry; Gemstone jewelry; Jewelry charms; Diamond jewelry; Gold jewelry; Custom jewelry; Men's jewelry; Women's jewelry; Pewter jewelry; Pendants as jewelry; Jewelry made of bronze; Jewelry made of crystal; Jewelry rings; Necklaces; Bracelets; Jewelry watches Wall decals; Works of art made of paper; Lithographic works of art; Removable stickers; Writing tablets; Paper cake toppers; Paper and cardboard; Paper bags and sacks; Framed art pictures; Bookmarks; Printed invitations; Blank note cards; Envelopes; Paper note tablets; Plastic shopping bags; Wrapping paper; Paper napkins; Paper cake decorations; Stationery; Stencils; Clipboards; Graphic art prints; Paper banners; Paper table cloths; Paper table linens; Coasters of cardboard; Art pictures on canvas; Printed publications, namely, brochures, booklets, and teaching materials in the field of intercollegiate athletics; Desk mats; Place mats of paper; Temporary tattoo transfers; Decals and stickers for use as home decor; Grocery bags; Graphic art reproductions; Gift bags; Paper tissues; Paper cocktail umbrellas; Cardboard signboards; Paper signboards; Coasters made of paper; Decals; Boxes, cartons, storage containers, and packaging containers made of paper or cardboard; Check book covers; Decorative decals for vehicle windows; Graphic fine art prints; Printed calendars; Paper stationery; Framed paintings; Art prints on canvas; Party ornaments of paper; Printed certificates for sports and/or entertainment fans; Paper handtowels; Printed paper signs; Flags of paper; Printed magazines featuring Texas Tech Athletics; Printed children's interactive educational books; Collectible printed trading cards; Printed newspaper cartoons; Padfolios; Printed children's storybooks; Printed cartoon strips; Floor signs being decals; Printed postcards; Printed greeting cards; Printed commemorative books featuring Texas Tech Athletics; Printed golf scorecards; Printed golf yardage books; Stickers; Printed story books; Printed wall maps; Decorative stickers for automobiles; Decorative vehicle bumper stickers; Printed cards bearing universal greetings; Framed photographs; Art prints comprised of digital illustrations originating from photographs; Art pictures in the nature of printed photographs; Printed photographs; Printed posters Wallets incorporating RFID blocking technology; Travel bags; Fanny packs; Briefcase-type portfolios; Book bags; Billfolds; Sling bags; Make-up bags sold empty; Multi-purpose purses; Purses not made of precious metal; Leather handbags; Leather credit card wallets; Leather briefcases; Duffle bags; Handbags; Suitcases; Briefcases; Baggage tags; Wallets and wallet inserts; Tote bags; Credit card cases; Credit card holders; Credit card wallets; Leather boxes; Luggage tags; All purpose sports bags; Luggage; Handbags, purses and wallets; Toiletry cases sold empty; Leather bags, suitcases and wallets; Back packs Picnic tables; Bar tables; Coffee tables; Folding tables; Side tables; Dining tables; Display tables; Camping tables; Occasional tables; Tables; Chairs; Inflatable chairs; Metal chairs; Bean bag chairs; Beach chairs; Office chairs; Desk chairs; Director's chairs; Rocking chairs; Lounge chairs; Camping chairs; Bar chairs; Bistro chairs; Patio chairs; Lawn chairs; Outdoor chairs; Upholstered chairs; Sofas; Benches; Stools; Ottomans Drinking glasses; Shot glasses; Wine glasses; Decanters; Insulated flasks; Ice buckets; Paper plates; Paper cups; Bowls; Decorative plates; Commemorative plates; Cleaning cloths; Leather coasters; Glass boxes; Beverageware; Coffee mugs; Knife boards; Wood chopping boards for kitchen use; Containers for household or kitchen use; Pastry cutters; Cookie jars; Drinking steins; Sports bottles sold empty; Cups; Mugs; Waste baskets; Salt and pepper shakers; Salad bowls; Cookie stamps; Trays for domestic purposes; Candle holders; Cutting boards; Pitchers; Serving platters; Serving dishes; Nutcrackers; Growlers; Barbecue forks; Ornaments of crystal; Pet feeding bowls; Ornaments of glass; Bird feeders; Cooking utensils, namely, grills Providing sports facilities; Providing sports news; Providing sports information; Organization of sports competitions; Sports ticket agency services; Coaching in the field of sports; Providing sports information via a website; Providing a web site that provides sports league player statistics; Sport camps; Providing collegiate athletic and sporting events
10.
IN VITRO BIOPRINTED BONE MODELS AND BIOINKS FOR BONE BIOPRINTING
Embodiments pertain to a bioink operational to form an artificial bone. The bioink includes a plurality of bone-related cells. Additional embodiments pertain to an artificial bone that includes a plurality of bone-related cells; and a bioink of the present disclosure that is embedded with the cells. The artificial bone may be in the form of a three-dimensional structure that includes a plurality of channels operational to allow fluid flow through the artificial bone. Further embodiments pertain to methods of making an artificial bone by applying a plurality of bone-related cells and a bioink onto a surface such that the bioink becomes embedded with the cells and forms a three-dimensional structure with a plurality of channels.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A mechanically robust LIG membrane can be fabricated by directly lasing a poly(ether) sulfone (PES) membrane support, the PES membranes being formed through a NIPS technique treated with Glycerol to control the pore collapse upon drying, to create a graphene layer on the top and/or bottom of the PES membrane.
Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.
C07C 275/30 - Dérivés d'urée, c.-à-d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné étant substitué de plus par des atomes d'halogène ou par des groupes nitro ou nitroso
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A burn bed system comprises a frame further comprising a first triangular shaped stand, a second triangular shaped stand, and at least one cross beam connecting the first triangular stand and the second triangular stand, and a mesh support assembly extending between the first triangular stand and the second triangular stand and configured to with straps to provide variable tension.
Provided herein is an in vivo swine model system, and methods for making and using the same, for an allergic condition, comprising: a pig sensitized to trigger an immune response for at least one of: allergy symptoms or anaphylaxis, wherein the allergy symptoms at triggered by repeated tape stripping (TS) of the skin and application of an allergen and an antigen, or wherein an immune response by intraperitoneal injections (IP), or both, with an allergen and an antigen once a week for up to six weeks.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
15.
TREATMENT OF RETINAL DEGENERATION WITH MINOCYCLINE AND MINOCYCLINE ANALOGS
Provided herein are molecules, compositions and methods for treating an ocular disease or disorder, comprising: administering to a subject an aqueous pharmaceutical composition, wherein the composition comprises a molecule, or a pharmaceutically acceptable salt thereof, and having reduced or no antimicrobial activity, wherein the molecule is selected from at least one of structure A, B, C, or D having the R-groups listed for each. The ocular disease or disorder is selected from the group consisting of abnormal angiogenesis, choroidal neovascularization (CNV), age-related macular degeneration (AMD), neovascular (exudative) age-related macular degeneration (nAMD), diabetic retinopathy, retinal vascular permeability, retinal edema, diabetic retinopathy, diabetic macular edema (DME), CNV associated with nAMD, sequela, associated with retinal ischemia, central retinal vein occlusion, and posterior segment neovascularization.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
C07D 317/44 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant deux atomes d'oxygène comme uniques hétéro-atomes du cycle comportant les hétéro-atomes en positions 1, 3 condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques
16.
PHARMACOLOGICAL AGONIST OF KLF2 REDUCES OSTEOCLAST DIFFERENTIATION, INFLAMMATION, AND COVID
Provided herein are compositions and methods for treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm with a molecule of formula: and one or more pharmaceutical acceptable excipients or salts; and methods for preventing and/or treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm triggered by a coronavirus 2 (SARS-CoV-2) infection or fibrosis in a subject.
A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:
A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:
A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:
wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.
C07C 237/26 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons du squelette carboné d'un cycle faisant partie d'un système cyclique condensé formé par au moins quatre cycles, p. ex. tétracycline
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
C07D 317/72 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant deux atomes d'oxygène comme uniques hétéro-atomes du cycle comportant les hétéro-atomes en positions 1, 3 condensés en spiro avec des carbocycles
18.
AD36E4ORF1 PEPTIDE FRAGMENTS AS ANTI-DIABETIC AGENTS
Embodiments of the present disclosure pertain to a composition that includes at least one early gene 4 open reading frame 1 (E4orfl) peptide fragment. The E4orfl peptide fragment includes, without limitation, SEQ ID NO: 1 or a sequence with at least 65% sequence identity to SEQ ID NO: 1; SEQ ID NO: 2 or a sequence with at least 65% sequence identity to SEQ ID NO: 2; or combinations thereof. Additional embodiments of the present disclosure pertain to methods of modulating cellular glucose uptake by associating cells with a composition of the present disclosure. Further embodiments of the present disclosure pertain to methods of treating or preventing a metabolic disorder in a subject by administering a composition of the present disclosure to the subject.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
19.
HERBICIDE RESISTANT HPPD VARIANTS IDENTIFIED VIA DIRECTED EVOLUTION
Embodiments of the present disclosure pertains to a modified plant or seed that includes a mutated 4-hydroxyphenylpyruvate dioxygenase (HPPD) gene. The mutated HPPD gene expresses an HPPD protein that confers herbicide resistance to the modified plant or seed. Additional embodiments of the present disclosure pertain to methods of producing modified plants or seeds by introducing a mutated HPPD gene to the plant or seed. The mutated HPPD gene may express a protein that includes SEQ ID NO: 1 or a sequence with at least 65% sequence identity to SEQ ID NO: 1. The mutated HPPD gene may also express a protein that includes SEQ ID NO: 2 or a sequence with at least 65% sequence identity to SEQ ID NO: 2.
Embodiments are directed to a fascial elevator tool configured to protect a medical professional's fingers while an incision is made, the tool including a fascial elevator configured to separate layers of tissue, a support arm connected to the fascial elevator, and a connector on the support arm, the connector, configured to connect to a surgical cutting tool.
A microwave passive sensor includes a microwave receiver, a low noise amplifier coupled to the microwave receiver, a mixer coupled to the low noise amplifier, and a baseband amplifier coupled to the mixer.
A61B 5/0507 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio utilisant des micro-ondes ou des ondes térahertz
22.
SYSTEM AND METHOD FOR BEHAVIORAL ANALYSIS OF SUSPICIOUS EVENTS AND MALICIOUS APPLICATIONS IN COMPUTER SYSTEMS
A method, non-transitory computer readable medium and system comprising receiving, at a computer system, data capturing a run time behavior of a binary object, extracting, with the computer system, the data from the run time behavior of the binary object, mapping, with the computer system, the extracted data into one or more interactive visual representations of the run time behavior of the binary object comprising a scalar representation of process calls, dependencies among processes and executable files, or time dependencies between the processes and the executable files, and classifying, with the computer system, the binary object as malicious or benign.
Embodiments of the present disclosure pertain to a plant or seed that includes one or more altered JASMONATE-ZIM DOMAIN repressor (JAZ) genes. Additional embodiments of the present disclosure pertain to methods of altering one or more JAZ genes of a plant or seed by introducing one or more alterations to the one or more JAZ genes of the plant or seed. The altered plants and seeds of the present disclosure may exhibit one or more altered properties, such as jasmonic acid (JA) insensitivity, enhanced resistance to pathogens, enhanced resistance to insects, enhanced fiber yield, enhanced fiber quality, or combinations thereof.
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
The present invention includes a method and device for storing hydrogen comprising: providing a mixture of a catalyst comprising a metal and a silicon oxide or carbon in a solvent; introducing a hydrogen into the solvent; and ultrasonically irradiating the mixture such that the hydrogen attaches to the catalyst to form hydrogenated catalyst; adding a fullerene into the solvent; and ultrasonically irradiating the hydrogenated catalyst and the fullerenes under conditions in which the hydrogen transfers from the catalyst to form a hydrogenated fullerene.
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
C01B 3/36 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants avec l'oxygène ou des mélanges contenant de l'oxygène comme agents gazéifiants
B01J 19/10 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des vibrations de fréquences audibles ou des ultrasons
25.
Intermediate Passive Wireless Loop Coil and Methods of Use Thereof
An intermediate passive wireless loop circuit includes one or more first loop coils, one or more second loop coils, and a set of interconnecting wires that series or parallel connect the one or more first loop coils to the one or more second loop coils such that the one or more first loop coils are separated from the one or more second loop coils by a distance.
H02J 50/10 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant un couplage inductif
H02J 50/40 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant plusieurs dispositifs de transmission ou de réception
H02J 50/50 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant des répéteurs d’énergie supplémentaires entre les dispositifs de transmission et les dispositifs de réception
26.
METHODS AND SYSTEMS FOR EVALUATING FIBER QUALITIES
Embodiments pertain to methods of evaluating fiber quality by (1) receiving at least one in-line hologram image of the fiber; (2) reconstructing the in-line hologram image of the fiber into at least one three-dimensional image of the fiber that includes fiber-related data; and (3) correlating the fiber-related data to fiber quality. Such methods may also include: (4) adjusting fiber-related conditions; and (5) repeating steps 1-3 after the adjustment. Further embodiments pertain to systems for evaluating fiber quality in accordance with the aforementioned methods. Such systems may include a receiving area with a region for housing a fiber, a light source associated with the receiving area, a chamber associated with the light source and receiving area, a camera within the chamber, a processor in electrical communication with the camera, a storage device, an algorithm associated with the storage device and a graphical user interface (GUI) associated with the processor.
Devices, methods and systems for producing functional textiles and electrically conductive composites including for electro-thermal membrane distillation using a reduced graphene oxide (rGO) coated membrane. The method includes introducing a feed solution to a membrane distillation module including rGO-coated membranes. The methods also includes applying a controlled voltage to the rGO-coated membrane. The method also includes generating joule heating. The joule heating locally heats the feed solution. The method also includes adjusting the controlled voltage. The method also includes volatilizing the target elements. The method also includes, responsive to the volatizing of the target elements, separating the target elements from the feed solution. The methods and systems producing functional textiles usable for electrochemical distillation of complex mixtures and for healthcare applications based on antimicrobial activity.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61L 15/00 - Aspect chimique des bandages, des pansements ou des garnitures absorbantes ou utilisation de matériaux pour leur réalisation
C02F 1/44 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dialyse, osmose ou osmose inverse
D06M 11/74 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du carbone ou ses composés avec du carbone ou du graphiteTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du carbone ou ses composés avec des carburesTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec du carbone ou ses composés avec des acides graphitiques ou leurs sels
D06M 16/00 - Traitement biochimique des fibres, fils, filés, tissus ou articles fibreux faits de ces matières, p. ex. enzymatique
D06M 23/06 - Procédés dans lesquels l'agent traitant est dispersé dans un gaz, p. ex. aérosols
D06M 23/08 - Procédés dans lesquels l'agent traitant est appliqué en poudre ou sous forme granulaire
28.
BIOACTIVE COMPOUNDS WITH PESTICIDE ACTIVITIES DERIVED FROM AGED CULTURES OF GREEN MICROALGAE
Embodiments of the present disclosure pertain to a composition suitable for use in treating an agricultural material. In some embodiments, the composition includes a microalgae culture, an extract of the microalgae culture, compounds from the microalgae culture, or combinations thereof. Additional embodiments of the present disclosure pertain to methods of treating an agricultural material by applying a composition of the present disclosure to the agricultural material.
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
The present invention includes compositions and method of treating a textile with an antimicrobial agent, the method comprising contacting the textile with an antimicrobial agent that comprises a reactive dye, carboxylic acid, or crosslinking agent comprising an organo-selenium compound in a treatment solution.
Methods for optimization of liquid oil production by huff-n-puff in shale reservoirs to achieve an improved (and optimal) oil recovery factor. The process determines and utilizes the optimum huff and puff times, number of cycles and soaking time under practical operation and reservoir conditions. The huff time in the process is a period so long that the pressure near the wellbore reaches the set maximum injection pressure during the huff period. The puff time in the process is the time required for the pressure near the wellbore to reach the set minimum production pressure during the puff period. Soaking is typically not necessary during the huff-n-puff gas injection in shale oil reservoirs. The number of huff-n-puff cycles is determinable by the time in which the economic rate cut-off is reached.
Hollow glass microspheres (HGMS) with a controlled nanotopographical surface structure (NSHGMS) demonstrate improved isolation and recovery of cells and other biological particles such as bacteria from biological fluid. Such functionalized HGMS are formed by exposing a plurality of hollow glass microspheres to a layer by layer deposition cycle of charged polymeric nanofilms to form a plurality of coated hollow glass microspheres and functionally binding a plurality of biotinylated antibodies to the plurality of coated hollow glass microspheres. Application of these HGMS in related biological particle isolation methods does not require specialized lab equipment or an external power source, and thus, can be used for separation of targeted cells from blood or other fluid in a resource-limited environment.
The present disclosure describes a self-sprayer device for self-administering an animal product to an animal and providing environmental enrichment to the animal.
A system and method for estimating an adsorption equilibria for one or more gases from pure component adsorption isotherms includes providing one or more processors, a memory communicably coupled to the one or more processors and an output device communicably coupled to the one or more processors, calculating an adsorption of each gas on a constant monolayer adsorption surface is calculated using the one or more processors and the generalized Langmuir isotherm equations (24)-(26) or equation (27), providing the adsorption of each gas to the output device, and developing a chemical process or product is developed using the adsorption of each gas.
G01N 25/48 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la production de quantités de chaleur, c.-à-d. la calorimétrie, p. ex. en mesurant la chaleur spécifique, en mesurant la conductivité thermique sur une solution, sorption ou réaction chimique n'impliquant pas une oxydation par combustion ou catalyse
G06F 17/11 - Opérations mathématiques complexes pour la résolution d'équations
A surgical training system, method, and apparatus comprise a biomaterial, a first clamp configured to engage the biomaterial and a second clamp configured to engage the biomaterial, at least one actuator operably connected to at least one of the first clamp and the second clamp wherein the at least one actuator is configured to impart tension in the biomaterial, and a patient body simulator arranged under the biomaterial.
The present invention includes a mutant DNase 1L3 having at least about a 95% identity with a nucleic acid sequence encoding the protein of SEQ ID NO: 2-8 for a mutant DNase 1L3 comprising at least one mutation for post-translational modification or attachment of a molecule to the mutant DNase 1L3 to increase the serum half-life of the mutant DNase 1L3, nucleic acids encoding the same, host cells, and methods of making the mutant DNase 1L3.
Methods and systems for pre-treatment of sludge and biosolids in preparation for electrochemical valorization is disclosed herein. Such methods can include selecting a sludge source; preparing a slurry, where the slurry comprises the sludge source and an electrolyte; adjusting a pH of the slurry, where the adjusting the pH of the slurry results in the slurry having an adjusted pH in a range between approximately 8 and 13; flowing the slurry through a first electrochemical cell, where the first electrochemical cell enables partial oxidation of the sludge via hydroxyl radicals; and flowing the partially oxidized slurry from the first electrochemical cell to a second electrochemical cell for selective conversion, where the second electrochemical cell includes an anode, a cathode, and a catalyst.
C02F 11/00 - Traitement des boues d'égoutDispositifs à cet effet
C02F 103/20 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de l'élevage d'animaux
C02F 103/32 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de l'industrie alimentaire, p. ex. eaux résiduaires de brasseries
C05F 3/00 - Engrais fabriqués à partir des excréments humains ou animaux, y compris le fumier
C05F 7/00 - Engrais fabriqués à partir des eaux résiduaires ou d'épandage, wagage, limon ou masses similaires
C05F 9/00 - Engrais fabriqués à partir des ordures ménagères ou de ville
37.
METHODS FOR STIMULATION OF NATURAL HYDROGEN PRODUCTION AND EXTRACTION THEREOF FROM EARTH'S SUBSURFACE
22) generation from Earth's subsurface, and extraction thereof. The methods include forming at least one well in contact with a source rock formation, wherein the at least one well is configured to allow the introduction of a fluid composition into the source rock formation, then introducing the fluid composition into the source rock formation. Thereafter, hydrogen gas production is stimulated from the source rock formation through a serpentinization process, and is subsequently extracted.
The present invention includes compositions and methods of treating CNS-related conditions, comprising: administering an effective amount of a compound that lowers the levels of one or more branched-chain amino acids (BCAAs) or metabolites thereof, or any pharmaceutically acceptable salt thereof, wherein the CNS-related conditions is selected from the group consisting of Alzheimer's disease and any related forms of dementia including vascular dementia, Lewy body dementia, frontotemporal dementia, Creutzfeldt-Jacob disease, Wernicke-Korsakoff disease, and Huntington's disease, Multiple sclerosis, Parkinson's disease, autism, Amyotrophic lateral sclerosis (ALS), Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and epilepsy.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Provided herein is a fusion protein, expression vector, nucleic acid, or method of making and using a first HLA-G monomer and a second HLA-G monomer connected by a linker peptide expressed as a single chain, and optionally, comprising a providence virus globulin domain to prevent or reduce neovascularization.
Methods and systems for electrocatalysis of municipal sludge and biosolids. Such methods (and systems thereof) include selecting a sludge source; preparing a slurry, where the slurry comprises the sludge source and an electrolyte; adjusting a pH of the slurry, where the adjusting the pH of the slurry results in the slurry having an adjusted pH in a range between approximately (8) and (14); flowing the slurry through an electrochemical cell, where the electrochemical cell includes an anode, a cathode, and a catalyst; applying a potential between the anode and the cathode, where applying the potential includes oscillating a cell voltage between the anode and the cathode at an oscillation frequency; resultant to the applying the potential, breaking down carbon bonds in the slurry with nitrogen and phosphorus; releasing inorganic nitrogen and inorganic phosphorus; and obtaining an electrolyzed sludge, where the electrolyzed sludge includes an electrolyzed solid comprising nitrogen and phosphorus.
A capillary-incorporated bioprinting system for rapid engineering of vascularized tissues, the system comprising a three-dimensional printing head, wherein the three-dimensional printing head is configured on a three-axis linear stage; a spinneret, wherein the spinneret is configured on a horizontal linear stage and the spinneret is affixed above the three-dimensional printing head; a UV light source, wherein the UV light source is operatively coupled to the three-dimensional printing head and the spinneret, and adjacent to the spinneret; and a pair of parallel bars, wherein the pair of parallel bars are configured to collect a plurality of electrospun aligned microtubes.
B29C 64/30 - Opérations ou équipements auxiliaires
B33Y 80/00 - Produits obtenus par fabrication additive
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
D01D 5/00 - Formation des filaments, fils ou similaires
42.
FOUR-COMPARTMENT CONTROLLER MODEL OF MUSCLE FATIGUE FOR ALL ACTIVITY TYPES
Embodiments pertain to a computer-implemented method of predicting muscle fatigue in a subject by: (1) receiving data related to muscle fatigue in a muscle of the subject; (2) feeding the data into an algorithm to predict the muscle fatigue; and (3) outputting the predicted muscle fatigue. The algorithm my include: (a) an active compartment (M_A) model representing individual motor units (MUs) generating force at full capacity, (b) a resting compartment (M_R) model representing inactive MUs capable of rapid activation into force production, (c) a centrally fatigued compartment (M_FC) model representing fatigued MUs due to a central mechanism dominant at zero or near-zero joint velocities, with rapid recovery, and (d) a peripherally fatigued compartment (M_FP) model representing fatigued MUs due to a peripheral mechanism dominant at higher velocities, with slow recovery. Further embodiments pertain to a computing device for predicting muscle fatigue in a subject in accordance with such methods.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
G16H 20/30 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies ou des activités physiques, p. ex. la physiothérapie, l’acupression ou les exercices
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
43.
NITRIC OXIDE MODIFIED ATMOSPHERE PACKAGING TO MAINTAIN BEEF COLOR
Embodiments of the present disclosure pertain to methods of packaging meat by associating the meat with a nitric oxide composition and a packaging unit. In some embodiments, the association of the meat with the nitric oxide composition and packaging unit includes: (1) placing the meat in the packaging unit; (2) flowing the composition into the packaging unit; and (3) sealing the packaging unit. Additional embodiments of the present disclosure pertain to packaging units that include meat and a nitric oxide composition. In some embodiments, the meat and the composition are sealed in the packaging unit.
Embodiments of the present disclosure pertain to methods of forming a co-crystallized composition by mixing a first molecule in a solid phase with a second molecule in a liquid phase to form a mixture, and then co-crystallizing the mixture to form the co-crystallized composition in the form of a crystalline solid. The mixing of the first and second molecules may occur through the utilization of mechanical force, such as milling. The co-crystallization of the first and second molecules may occur by adding a solvent to the mixture of the molecules and then evaporating the added solvent. The methods may also include a step of utilizing the co-crystallized composition as seed crystals to grow additional co-crystallized compositions. Further embodiments of the present disclosure pertain to the formed co-crystallized compositions.
C07D 213/74 - Radicaux amino ou imino substitués par des radicaux hydrocarbonés ou par des radicaux hydrocarbonés substitués
C07D 213/38 - Radicaux substitués par des atomes d'azote liés par des liaisons simples comportant uniquement de l'hydrogène, ou des radicaux hydrocarbonés, liés à l'atome d'azote substituant
45.
EQUINE ALLERGIC AIRWAY DIAGNOSIS AND ENVIRONMENTAL AIR AND ALLERGEN ASSESSMENT
A monitoring system for equine allergic airway diagnosis and environmental and air allergen assessment comprises a collection muzzle, a sensor in fluidic connection with the collection muzzle, an environmental sensor disposed in an environment proximate to the collection muzzle, and a chemical sensor disposed in the environment proximate to the collection muzzle.
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
Inventeur(s)
Abbruscato, Thomas J.
Nozohouri, Saideh
Zhang, Yon
Trippier, Paul
Kumari, Shikha
Karamyan, Vardan T.
Esfahani, Shiva Hadi
Jayaraman, Srinidhi
Maddeboina, Krishnaiah
Jonnalagadda, Shirisha
Abrégé
Provided herein are novel compositions and methods for enhancing neurolysin activity comprising: a molecule of Formula I, II, III, or IV a salt, or enantiomer thereof:
A system and method for categorizing and assessing wells comprises: retrieving by one or more processors, a geologic seal penetration data, a geologic storage reservoir penetration data, an underground source of drinking water protection data, a geologic seal protection data and a geologic storage reservoir protection data for one or more wells from a database; categorizing by the one or more processors, the one or more wells as a well type based on the retrieved data; obtaining by the one or more processors, a status of the one or more wells from the database; assessing by the one or more processors, an action priority of the one or more wells based on the well type and the status; and providing by the one or more processors, the action priority of the one or more wells to one or more devices communicably coupled to the one or more processors.
E21B 41/00 - Matériel ou accessoires non couverts par les groupes
E21B 33/13 - Procédés ou dispositifs de cimentation, de bouchage des trous, des fissures ou analogues
E21B 43/16 - Procédés de récupération assistée pour l'extraction d'hydrocarbures
E21B 47/117 - Détection de fuites, p. ex. du tubage, par test de pression
E21B 49/00 - Test pour déterminer la nature des parois des trous de forageEssais de couchesProcédés ou appareils pour prélever des échantillons du terrain ou de fluides en provenance des puits, spécialement adaptés au forage du sol ou aux puits
48.
VACUUM CALORIMETER COMPRISING AN OPEN SYSTEM DIFFERENTIAL CALORIMETER
An open calorimetry system is configured to measure heat flow from, and power out of or into, a working substance. The working substance can interact with the environment, allowing heat and mass to enter and leave. The embodiments are configured to measure power over five orders of magnitude from 100 μW to 50 W in a normal room temperature environment.
Embodiments of the present disclosure pertain to a method of assessing a disease in a subject by receiving a biological sample of the subject; detecting a single nucleotide polymorphism at codon 72 of the P53 protein (SNP) from the biological sample; and correlating the detected SNP to disease prognosis in the subject. Further embodiments pertain to methods of treating a subject by detecting an SNP from a biological sample of the subject and editing the detected SNP to treat or prevent a disease in the subject. Additional embodiments pertain to diagnostic tests and computing devices for assessing a disease in a subject in accordance with the methods of the present disclosure.
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
Disclosed is a system and method for a microdevice to separate blood cells based on differences in antigen expression. Specifically, cells of the same phenotype are separated based on whether or not they are activated during infection or resting. The device of the present disclosure takes a small sample of blood and provides differential cell counts that can be used to test for infection and inflammatory response. The device can be used to identify sepsis and other infections rapidly. By measuring differences in activated white cell counts such as neutrophils, the device of the present disclosure measures physiological response to infection in hospitalized patients recovering from burns, surgeries, etc.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
51.
DELIGNIFICATION OF MATERIALS IN DEEP EUTECTIC SOLVENTS
Embodiments of the present disclosure pertain to methods of removing lignin from a material by associating the material with a deep eutectic solvent (DES) that includes at least one hydrogen bond acceptor (HBA) and at least one hydrogen bond donor (HBD). The methods of the present disclosure may also include one or more steps of heating the solvent-associated material, separating the material from the solvent, drying the material, washing the material, and/or processing the material. Additional embodiments of the present disclosure pertain to delignified materials that are formed in accordance with the methods of the present disclosure.
A method, system, and apparatus for improving wind harvest efficiency comprises: a wind turbine, a processor, and a computer-usable medium embodying computer code, said computer-usable medium being coupled to said processor, said computer code comprising non-transitory instruction media executable by said processor configured for: setting a desired location range of a wind wake with a controller, determining an error signal indicative of a difference between a currently measured cross-stream thrust component of wind and an optimal cross-stream thrust component of wind, adjusting a speed of a rotor associated with the wind turbine according to the error signal, and confining a real-time position of the wind wake to the desired location range of the wind wake.
F03D 7/02 - Commande des mécanismes moteurs à vent les mécanismes moteurs à vent ayant l'axe de rotation sensiblement parallèle au flux d'air pénétrant dans le rotor
53.
GLYCINE RECEPTORS IN WHITE BLOOD CELLS AS BIOMARKERS FOR PAIN
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Dou, Huanyu
Xu, Yan
Abrégé
Embodiments of the present disclosure pertain to methods of assessing pain in a subject by receiving one or more measured levels of glycine receptors of the subject; and correlating differentially expressed levels of the glycine receptors to pain. The methods of the present disclosure may also include a step of implementing a treatment decision based on the assessment. In some embodiments, the methods of the present disclosure may be repeated after implementing the treatment decision. Additional embodiments of the present disclosure pertain to systems for assessing pain in a subject. In some embodiments, the systems include computer-readable storage mediums with program codes that implement the methods of the present disclosure.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
54.
METHOD AND DEVICE FOR DETECTING SUBCLINICAL HYPOXEMIA USING WHOLE BLOOD T2P
Embodiments of the present disclosure pertain to methods of detecting hypoxemia in a subject by: (1) receiving a blood sample from the subject; (2) measuring the T2 relaxation time constant of the blood cell (e.g., blood cell pellet) of the blood sample (T2P value); and (3) correlating the measured T2P value to hypoxemia. In some embodiments, the methods of the present disclosure also include a step of correlating the measured T2P value to the subject's susceptibility to one or more hypoxemia-related conditions. Further embodiments of the present disclosure pertain to systems for detecting hypoxemia in a subject in accordance with the methods of the present disclosure.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
55.
METHOD AND DEVICE FOR DETECTING SUBCLINICAL HYPOXEMIA USING WHOLE BLOOD T2p
Embodiments of the present disclosure pertain to methods of detecting hypoxemia in a subject by: (1) receiving a blood sample from the subject; (2) measuring the T2 relaxation time constant of the blood cell (e.g., blood cell pellet) of the blood sample (T2P value); and (3) correlating the measured T2P value to hypoxemia. In some embodiments, the methods of the present disclosure also include a step of correlating the measured T2P value to the subject's susceptibility to one or more hypoxemia-related conditions. Further embodiments of the present disclosure pertain to systems for detecting hypoxemia in a subject in accordance with the methods of the present disclosure.
G01N 33/72 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les pigments du sang, p. ex. l'hémoglobine, la bilirubine
56.
SYSTEMS AND METHODS FOR IDENTIFYING AND ALERTING OF FOOTPRINT OVER-CYCLE RISKS ON MULTI-PRODUCT GENERAL ASSEMBLY LINES
A system includes a module configured to, for each footprint of a conveyor, identify vehicle groups having different vehicle characteristics and over-cycle distributions for each vehicle group or a back-to-back sequence of any given vehicle group by calculating, for each vehicle characteristic, over-cycle distributions for a first vehicle group having the vehicle characteristic and a second vehicle group not having the vehicle characteristic, determining whether either the number of vehicles in the first or second vehicle group or a difference between the over-cycle distributions for the first and second vehicle groups satisfies a threshold condition, and in response, cease identifying the vehicle groups. The module is configured to identify, for a received actual vehicle sequence, over-cycle risks based on the identified vehicle groups and the over-cycle distributions for each vehicle group or a back-to-back sequence of any given vehicle group. Other examples systems and methods are also disclosed.
A method for simulating conveyors includes receiving conveyor content for each cycle, the conveyor content including over-cycle distributions each specific to a vehicle group at a footprint of each conveyor for a footprint cycle time, determining a cumulative probability, for each footprint cycle time, across all of the footprints of the conveyor, of one or more of the footprints of the conveyor having that cycle time or less, and determining an individual probability, for each footprint cycle time, across all of the footprints of the conveyor, of the conveyor having that cycle time. The method further includes receiving a vehicle dispatch strategy and generating an alert indicating an over-cycle risk for the strategy based on the individual probabilities, and/or performing a discrete event simulation of the conveyors using one of the individual probabilities for each cycle and for each conveyor. Other examples systems and methods are also disclosed.
CSPP devices, methods of fabricating CSPP devices, and systems with CSPP devices are provided. The CSPP devices of this disclosure a polar dielectric substrate, an insulator layer disposed on the polar dielectric substrate. The polar dielectric substrate having a phonon polariton surface contacting the insulator layer. A grating including a plurality of grating structures is disposed on a plasmon polariton surface of the insulator layer such that adjacent grating structures of the plurality of grating structures form gaps therebetween. The insulator layer is exposed in each of the gaps and FP cavities are in the insulator layer under each of the grating structures, the FP cavities having a FP refractive index different than a refractive index of the regions of the insulator layer exposed by the gaps. The CSPP devices allow for phase modulation at longer infrared wavelengths and have a resonance due to the array of FP cavities.
G01N 21/3581 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge lointainCouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant un rayonnement térahertz
G02F 1/21 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence
G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
G01J 3/18 - Production du spectreMonochromateurs en utilisant des éléments diffractants, p. ex. réseaux
G01J 3/26 - Production du spectreMonochromateurs en utilisant une réflexion multiple, p. ex. interféromètre de Fabry-Perot, filtre à interférences variables
09 - Appareils et instruments scientifiques et électriques
Produits et services
Downloadable software mobile apps for health and diet monitoring; downloadable educational mobile applications for personal development, health and nutrition tracking; downloadable software for educational services, namely, software for providing information related to health and nutrition
60.
SEAMLESS MODE CHANGE BETWEEN GRID-CONNECTED MODE AND ISLANDED MODE FOR PV SYSTEMS
A unified control scheme to achieve seamless mode change between grid-connected mode and islanded mode for photovoltaic (PV) systems includes two decoupled control units: a DC-DC converter control unit and a DC-AC converter control unit. The DC-bus voltage is controlled through the DC-DC converter control unit, which supplies a “stiff DC source” to the DC-AC converter. The seamless mode change is implemented in the DC-AC converter control module via three digital switches between power flow control for grid-connected mode (or MPPT mode), and droop control for islanded mode (or droop mode), while preserving the continuity of control signals in all control units with the configurations of digital switches.
Provided herein are methods for the preparation of chitin nanocrystals, nanowhiskers, or both directly from a raw chitinous biomass without the prior isolation of a raw chitin polymer using an ionic liquid comprising: drying the raw chitinous biomass; and extracting in a single step a purified chitin by hydrolyzing with an ionic liquid from a raw, unpurified chitinous biomass, wherein the chitin nanocrystals and nanowhiskers comprise at least one of a high aspect ratio, are highly crystalline, or have high thermal stability.
A method for recovering target metal ions from a fluid stream using a chemically enhanced electrodialysis membrane, the method including selecting a cation-exchange membrane comprising a surface, synthesizing an ion sequestrant, wherein the ion sequestrant is capable of binding the target metal ions, grafting the ion sequestrant onto the cation-exchange membrane, wherein the grafting results in a thin layer of the ion sequestrant being affixed to the surface of the cation-exchange membrane, placing the cation-exchange membrane in an electrodialysis unit, wherein the electrodialysis unit comprises an anode, a cathode, and a diluate chamber, passing a diluate stream through the diluate chamber, wherein the diluate stream comprises the target metal ions, passing the diluate stream through the thin layer of the ion sequestrant affixed to the surface of the cation-exchange membrane, and binding the target metal ions to the cathode-exchange membrane.
C02F 1/469 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par séparation électrochimique, p. ex. par électro-osmose, électrodialyse, électrophorèse
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 71/82 - Matériaux macromoléculaires non prévus spécifiquement dans un seul des groupes caractérisés par la présence de groupes déterminés, p. ex. introduits par un post-traitement chimique
C02F 103/06 - Eau souterraine contaminée ou eau de lessivage
C02F 103/10 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de carrières ou d'activités minières
C02F 103/36 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de l'industrie chimique non prévue dans les groupes provenant de la fabrication de composés organiques
63.
SONOCHEMICAL SYNTHESIS METHODS AND RELATED APPLICATIONS
B01J 23/00 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe
B01J 23/83 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du cuivre ou des métaux du groupe du fer en combinaison avec des métaux, oxydes ou hydroxydes prévus dans les groupes avec des terres rares ou des actinides
C01B 3/38 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants avec des catalyseurs
C01B 3/34 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants
64.
GFRA2 ANTIBODIES AND THEIR USE IN CANCER TREATMENT
Embodiments of the present disclosure pertain to an antibody that binds to GDNF family receptor alpha 2 (GFRA2), where the antibody may be in a modified form that includes, without limitation, a humanized form, a bispecific antibody, a chimeric form, a drug conjugated form, a bispecific form, an immunocytokine form, a labeled form, a fragmented form, or combinations thereof. Additional embodiments pertain to methods of treating or preventing a cancer in a subject by administering to the subject an antibody of the present disclosure. Further embodiments pertain to methods of diagnosing a subject with a GRFA2 positive cancer by exposing a specimen from the subject to an antibody of the present disclosure. Additional embodiments pertain to chimeric antigen receptor T-cells that express an antibody of the present disclosure and methods of treating or preventing a cancer in a subject by administering them to the subject.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
65.
FABRICATION OF SUPERCAPACITORS WITH INKJET PRINTED MANUFACTURING
Embodiments described herein provide for metal-insulator-metal (MIM) capacitors, supercapacitors of MIM capacitors, and a method of forming MIM capacitors and supercapacitors. The MIM capacitors and supercapacitors include a plurality of capacitors disposed over each other, each capacitor includes a first conductive layer disposed over a substrate, a dielectric layer disposed on the first conductive layer, and a second conductive layer disposed on the dielectric layer.
The present invention includes composition and methods for making and using a selenium-carrier conjugate for in vivo administration comprising: covalently attaching a selenium compound that reacts in vivo with naturally occurring reduced thiols and oxygen to produce superoxide, which can include a Fenton Complex that allows for a generation of hydroxyl radicals, and that wherein the selenium-carrier conjugate is stabilized against enzymatic degradation and clearance from the body and the synthetic targeting carrier binds target.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 33/04 - Soufre, sélénium ou tellureLeurs composés
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Provided herein are compositions and methods for making a guar-based composite material comprising: a guar gum comprising 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, or 50% weight to weight of the composite; a cellulose comprising 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, or 50% weight to weight of the composite; and optionally a plasticizer, wherein the composite has a higher flexibility and tensile strength than either the guar gum or cellulose alone
The present invention relates to a method and apparatus for passive collection of sperm having improved motility from a semen sample. The semen sample is contacted with on side of a porous barrier and a nutrient-containing media is contacted with the other side of the porous barrier. More robust sperm migrate from the semen sample through the porous barrier and are collected in a nutrient-containing media.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, providing courses of instruction at the university level, and arranging and conducting educational conferences and academic exhibitions in the field of university academics; entertainment services, namely, arranging and conducting athletic competitions, athletic tournaments, and athletic exhibitions; entertainment services, namely, arranging and conducting live performances by musical groups and music festivals for cultural or entertainment purposes
70.
NANOPARTICLE SIZE AND ELEMENTAL COMPOSITION CHARACTERIZATION
Embodiments of the present disclosure pertain to methods of identifying one or more characteristics of particles by (1) placing the particles on a surface; (2) exposing the particles to an ion to result in emissions from the particles; (3) measuring the emissions from the particles; (4) generating an emission profile from the measured emissions; and (5) correlating the generated emission profile to one or more characteristics of the particles
The present invention includes a method of activating, modulating, and/or anergizing an immune response by targeting the junctional epithelia in the gingival crevice.
A rammed earth brick forming system comprises a compaction assembly configured to accept earthen material for compaction, a sub-frame assembly, wherein the compaction assembly is mounted to the compaction assembly, and an extractor configured to transport a finished brick out of the compaction assembly.
B28B 3/04 - Fabrication d'objets façonnés en utilisant des pressesPresses spécialement adaptées à ce travail dans laquelle un poinçon exerce une pression sur le matériau dans une cavité de moulagePoinçons de forme particulière avec un poinçon par moule
73.
Method of Treating Cancer With Atpenin A5 Derviatives
The present invention includes molecules, composition, and methods for making and using a molecule having the formula:
The present invention includes molecules, composition, and methods for making and using a molecule having the formula:
The present invention includes molecules, composition, and methods for making and using a molecule having the formula:
wherein R′ is selected from H, methoxy, methoxymethyl, glycosyl, phosphoryl, alkylamine, polyethylene glycol (PEG), or deuterated; X is selected from OH, methoxy, methoxymethyl, O-methoxymethyl, carbonyl, or alcohol; Y is O; and R″ is selected from H, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, or dodecyl, that are saturated or unsaturated, PEG, or triphenylphosphate groups; optionally one or both MeO groups are deuterated; and N is N-oxide or N-alkyl.
SELECTIVE AND NON-SELECTIVE OPIOID RECEPTOR FUNCTIONAL ANTAGONISTS AND METHODS RELATED THERETO FOR TREATMENT OF ADDICTION, OPIOD DEPENDENCE, AND NEUROPATHIC PAIN
Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as addiction, alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, fibromyalgia, and combinations thereof. The compounds act by acting as selective antagonist to the kappa (κ) opioid receptor. Further, disclosed compounds are an analog compound that can act as an antagonist to one or more opioid receptors. When present, these compounds lead to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner. The disclosed compounds are shown to be effective in the nanomolar range.
Embodiments of the present disclosure pertain to computer-implemented methods of predicting an outcome of a cardiac procedure in a subject by (1) receiving a plurality of health-related data from the subject; (2) feeding the health-related data into a risk prediction model that integrates the health-related data and predicts one or more outcomes of the cardiac procedure; and (3) generating an output from the risk prediction model, where the output includes the predicted outcomes of the cardiac procedure. The methods of the present disclosure may also include a step of (4) recommending a treatment decision based on the predicted outcomes of the cardiac procedure. Additional embodiments of the present disclosure pertain to a computing device that is operable for predicting an outcome of a cardiac procedure in a subject.
The disclosed embodiments are directed to a guide system comprising a cradle configured to couple to a probe and a guide structure configured to couple to a limb of a patient, the guide structure comprising a fastening component and at least two strips configured to connect to the fastening component, wherein each of the at least two strips further comprises a guide track formed thereon, wherein the probe cradle is configured to travel along the at least two strips.
A61B 90/50 - Supports pour instruments chirurgicaux, p. ex. bras articulés
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
77.
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER
A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect amount of at least one of PRIMA-1 or APR-246 to the patient.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Embodiments of the present disclosure pertain to methods and systems for assessing a subject's vulnerability to developing at least one cardiometabolic-related condition. Such methods and systems generally include the following steps or instructions: (1) receiving a plurality of health-related data of the subject; (2) calculating a risk score from the plurality of health-related data; (3) correlating the risk score to the subject's vulnerability to the cardiometabolic-related condition; and (4) making a treatment decision based on the subject's vulnerability to the cardiometabolicrelated condition.
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16B 25/00 - TIC spécialement adaptées à l’hybridationTIC spécialement adaptées à l’expression de gènes ou de protéines
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
79.
APPARATUS AND METHOD FOR COLLECTION OF SPERM SAMPLES
The present invention relates to a method and apparatus for passive collection of sperm having improved motility from a semen sample. The semen sample is contacted with on side of a porous barrier and a nutrient-containing media is contacted with the other side of the porous barrier. More robust sperm migrate from the semen sample through the porous barrier and are collected in a nutrient-containing media.
The disclosed embodiments are directed to an eVTOL aircraft comprising a fuselage, wings mounted to the fuselage, where the wings comprise an undercambered lower surface, and an array of ducted fans mounted to the undercambered lower surface, wherein each fan in the array of ducted fans further comprises a duct and a plurality of rotor blades, each of the plurality of rotor blades comprising a zero sweep leading edge and an elliptical trailing edge.
A nonlinear radar system includes a first antenna configured to generate and emit an incident signal having a first frequency, a transponder tag attached to an existing portable object, wherein the transponder tag includes an electromagnetic nonlinear element configured to be detected by the incident signal. Upon being detected by the incident signal, the transponder tag is configured to transmit a reflected return harmonic signal having a second frequency different from the first frequency, wherein the reflected return harmonic signal is an on-off keying (OOK) signal. A second antenna is configured to receive the reflected return harmonic signal having the second frequency. The transponder tag includes a conductive layer in electrical communication with the electromagnetic nonlinear element including a Schottky diode.
The disclosed embodiments are directed to helmet systems including a helmet shell, energy-absorbing suspension pads, and an adjustable retention system, further including fluorescent and retroreflective trim, ear covers, and a face shield or visor or both. The configuration can be configured to pass NFPA standard tests, which can include helmet shell impact and thermal tests, and penetration tests. In addition, the helmet can be designed to facilitate the integration of other ancillary accessories such as communication and lighting systems.
A system for training detection dogs comprising a central computer; a plurality of olfactometers operably connected to the central computer, each olfactometer comprising one or more sampling ports; a plurality of odor channels in fluid communication with the sampling port; an independent controller operably coupled to the plurality of odor channels; and one or more sensors connected to the one or more sampling port; a cover disposed to the one or more covers and uncover one or more of the one or more sampling ports; a cover controller operably coupled to the one or more covers; and a feeder operably coupled to the cover controller.
The present invention includes composition and methods of delivering one or more nutrients to a subject comprising: delivering an effective amount of one or more nutrients into a gingival crevice wherein the amount is sufficient to supplement the diet of the subject for the nutrients.
A23L 27/00 - ÉpicesAgents aromatiques ou condimentsÉdulcorants artificielsSels de tableSubstituts diététiques du selLeur préparation ou leur traitement
A23L 33/16 - Sels inorganiques, minéraux ou oligo-éléments
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
09 - Appareils et instruments scientifiques et électriques
Produits et services
Downloadable electronic files in the nature of school yearbook materials, namely, data, text and images; electronic publications, namely, school yearbooks, recorded on computer media; downloadable electronic files in the nature of articles, digital data, text and images in the field of historical preservation.
86.
LISTERIA MONOCYTOGENES AS A VECTOR FOR TUMOR-SPECIFIC DELIVERY OF CHEMOTHERAPEUTIC AGENTS
Listeria monocytogenesListeria monocytogenes bacterium (Listeria) that is associated with at least one therapeutic agent. The therapeutic agent may be associated with a surface of the Listeria through a Listeria binding agent. The therapeutic agent may also be covalently associated with the surface of the Listeria through a cleavable linker that directly links the therapeutic agent to the surface of the Listeria. Additional embodiments of the present disclosure pertain to methods of delivering at least one therapeutic agent to a subject by administering to the subject a Listeria of the present disclosure. Further embodiments of the present disclosure pertain to methods of making a Listeria of the present disclosure by associating the Listeria with at least one therapeutic agent.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
Embodiments of the present disclosure pertain to methods of treating or preventing a condition in a subject by administering to the subject a composition having alpha-methyl-L-tryptophan. In additional embodiments, the method further includes a step of instructing the subject to administer the composition in order to treat or prevent the condition in the subject. In some embodiments, the condition includes, without limitation, hyperglycemia, diet-induced diabetes, high-fat diet-induced diabetes, insulin resistance, metabolic syndrome, extra weight, obesity, hepatic steatosis, and combinations thereof. Additional embodiments of the present disclosure pertain to compositions for use in treating or preventing a condition in a subject. In some embodiments, the composition includes alpha-methyl-L-tryptophan.
A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
Embodiments of the present disclosure pertain to a composition that is suitable for use in treating or preventing arterial stiffness in a subject. In some embodiments, the composition includes a recombinant human thioredoxin (rhTrx), derivatives thereof, peptide fragments thereof, mutants thereof, or combinations thereof. Additional embodiments of the present disclosure pertain to methods of treating or preventing arterial stiffness in a subject by administering the compositions of the present disclosure to the subject.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The disclosed embodiments are directed to a modular autonomous vehicle system comprising a blended wing body module, at least two high speed long range wing panel modules configured to interchangeably mount to the blended wing body module, at least two low speed high endurance wing panel modules configured to interchangeably mount to the blended wing body module, a vertical tails module configured to interchangeably mount to the blended wing body module, a vertical takeoff and landing fin module configured to interchangeably mount to the blended wing body module, a power train, and a wheels module with a plurality of wheels operably connected to the power train.
B60L 50/60 - Propulsion électrique par source d'énergie intérieure au véhicule utilisant de la puissance de propulsion fournie par des batteries ou des piles à combustible utilisant de l'énergie fournie par des batteries
91.
CELL-LADEN BIOINK CIRCULATION-ASSISTED INKJET-BASED BIOPRINTING TO MITIGATE CELL SEDIMENTATION AND AGGREGATION
A system for active circulation of bioink in inkjet bioprinting, comprises a bioink reservoir, an inlet connected to a pump, an outlet from the pump to the bioink reservoir, wherein the pump circulates bioink from the inlet to the outlet.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
B33Y 70/10 - Composites de différents types de matériaux, p. ex. mélanges de céramiques et de polymères ou mélanges de métaux et de biomatériaux
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
92.
Golf ball locating nonlinear radar system employing a snowflake nonlinear passive tag and associated method(s)
A nonlinear radar system includes a handheld unit including a display screen, a first antenna configured to generate and emit an incident signal having a first frequency, and a second antenna configured to receive a reflected return harmonic signal having a second frequency, as well as a transponder tag is attached to an existing golf ball. Such a transponder tag is in communication with and responsive to the handheld unit, and includes an electromagnetic nonlinear element configured to be detected by the incident signal without the need for a line of sight. Upon being detected by the incident signal, the transponder tag is configured to transmit the reflected return harmonic signal having the second frequency different from the first frequency. The transponder tag is passive and does not require a power source other than incident radiation.
G01S 13/75 - Systèmes utilisant la reradiation d'ondes radio, p. ex. du type radar secondaireSystèmes analogues utilisant des transpondeurs alimentés par les ondes reçues, p. ex. utilisant des transpondeurs passifs
G01S 7/02 - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe
G01S 7/03 - Détails de sous-ensembles HF spécialement adaptés à ceux-ci, p. ex. communs à l'émetteur et au récepteur
G01S 13/88 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques
G01S 13/00 - Systèmes utilisant la réflexion ou la reradiation d'ondes radio, p. ex. systèmes radarSystèmes analogues utilisant la réflexion ou la reradiation d'ondes dont la nature ou la longueur d'onde sont sans importance ou non spécifiées
93.
MODIFIED PLANTS AND SEEDS WITH ENHANCED PHYSIOLOGICAL PERFORMANCE AND ENVIRONMENTAL STRESS RESISTANCE
Embodiments of the present disclosure pertain to methods of enhancing a physiological performance or environmental stress resistance of a plant or seed by exposing the plant or seed to a composition that includes ethanol, acetic acid, or combinations thereof. Additional embodiments of the present disclosure pertain to modified plants or seeds that demonstrate enhanced physiological performance, enhanced environmental stress resistance, or combinations thereof. In some embodiments, the modified plants or seeds are formed by exposing the plants or seeds to a composition of the present disclosure. In some embodiments, the enhanced physiological performance or environmental stress resistance may occur through inheritable epigenetic modifications in the plant or seed.
a hyperuniform-structured microchip is disclosed, which is capable of providing viable resolution of CTC subpopulations supporting the ability to determine whether there is a correlation between CTC heterogeneity and tumor progression.
Disclosed is a catheter tubing having surface expression of organo-selenium compositions capable of presenting anti-microbial properties on the surface of the catheter tubing which prevent microbial growth and the formation of biofilms. The disclosed compositions and methods support a wide variety of scenarios for catheter tubing applications, as organo-selenium can be stably incorporated into catheter tubing to inhibit bacterial attachment, growth, and biofilm formation for multiple uropathogenic organisms for long-term use with minimal to no leaching.
Provided herein is a method and system for detecting kinase activity, comprising: providing one or more mutated kinases, wherein the one or more mutated kinases comprise a mutation that enlarges an ATP binding pocket of the kinase; contacting the one or more mutated kinases with an ATP or ADP analog-nanoparticle conjugate capable of intracellular delivery of the ATP or
Provided herein is a method and system for detecting kinase activity, comprising: providing one or more mutated kinases, wherein the one or more mutated kinases comprise a mutation that enlarges an ATP binding pocket of the kinase; contacting the one or more mutated kinases with an ATP or ADP analog-nanoparticle conjugate capable of intracellular delivery of the ATP or
ADP analog-nanoparticle conjugate, wherein the ATP or ADP analog comprises a detectable label; assaying the one or more mutated kinases under conditions in which the ATP or ADP analog-nanoparticle conjugate contacts the one or more mutated kinases, wherein the one or more kinases react to transfer the detectable label to the substrate, wherein the ATP analog only fluoresces upon contact with the ATP binding pocket of the kinase.
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
A system and method of producing ammonia comprises reacting a nitrogen feed gas and a hydrogen feed gas in a reactor to form ammonia, wherein the reaction produces a reaction mixture comprising ammonia gas, unreacted nitrogen and unreacted hydrogen, absorbing the ammonia from the reaction mixture in an absorber column containing an absorber, the absorber comprising a support and a metal halide, outputting the ammonia absorbed by the absorber, and recycling the unreacted nitrogen and unreacted hydrogen.
Embodiments of the present disclosure pertain to methods of treating or preventing cancer in a subject by administering to the subject a composition that includes at least one of the compounds disclosed herein. The cancer to be treated or prevented can include, without limitation, lung cancer, breast cancer, cancers associated with an over-expression of a ral interacting protein, or combinations thereof. Further embodiments of the present disclosure pertain to the compositions of the present disclosure.
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
Embodiments of the present disclosure pertain to methods of treating or preventing a disorder in a subject by administering to the subject a composition that includes one or more of the following active components: a zinc finger protein ZPR1 (ZPR1), an analog thereof, a homolog thereof, a derivative thereof, or combinations thereof; an enhancer of expression of ZPR1, an analog thereof, a homolog thereof, or combinations thereof; nucleotides encoding ZPR1, an analog thereof, a homolog thereof, a derivative thereof, or combinations thereof; or combinations thereof. The disorder to be treated or prevented may be caused by at least one mutation in the Senataxin (SETX) gene, a downregulation of SETX protein levels, or may include a neurodegenerative disease or disorder. Further embodiments pertain to the aforementioned compositions, which may be suitable for use in treating or preventing one or more of the aforementioned disorders in a subject.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention includes a method and food product made by at least partially enclosing a food product with a water-permeable membrane; and contacting a brine or sugar solution with a water activity sufficiently high to draw water molecules across the water-permeable membrane and away from the food product to preserve the food.
A23L 13/77 - Morceaux de viande attendris ou aromatisésSolutions de macération ou de marinage spécialement adaptées à cet effet par traitement mécanique, p. ex. par pétrissage, frottage ou barattage
